A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a consensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.
Goodwin
J W
JW
Ozarks CCOP, Springfield, MO.
Crowley
J
J
Eyre
H J
HJ
Stafford
B
B
Jaeckle
K A
KA
Townsend
J J
JJ
D005260:Female; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D008579:Meningioma / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy / Q000601:surgery; D016879:Salvage Therapy; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D013629:Tamoxifen